NORP – Talk Bio

JPM26: BMS Highlights Early-Stage Bets and Pipeline Progress Amid Late-Stage Pharma Focus

3 days ago talkbio0Tagged Admilparant, Burning Mouth Syndrome, Camzyos, Cobenfy, Early-stage, JPM26, milvexian, pipeline, pumitamig

BMS; JPM26; early-stage bets; pipeline; Cobenfy; Milvexian; Admilparant; Pumitamig; Camzyos

Lilly Bulks Up Inflammatory Pipeline With $1.2B Ventyx Buy, InduPro Cancer Pact

7 days ago talkbio0Tagged Autoimmune, cardiometabolic, Eli, Eli Lilly, Immunotherapy for cancer, InduPro * *, Inflammatory disorder, M&A, Neoplasms, Neuroinflammation, NLRP3 inhibitors, Obesity, Ventyx Biosciences, VTX3232, VTX958

Eli Lilly; Lilly; Ventyx Biosciences; InduPro; inflammatory diseases; oncology; NLRP3 inhibitors; tamuzimod; VTX2735; VTX3232; VTX958; autoimmune; obesity; cardiometabolic; neuroinflammation; M&A; biotech deal; cancer immunotherapy

Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets

1 week ago talkbio0Tagged cancer drug development, Capital, Fibromatosis, Aggressive, fidelity, FOG-001, FogPharma, Helicon peptide platform, Janus Henderson, Malignant neoplasm of prostate, Parabilis Medicines, Rheumatoid Arthritis, Series F financing, targets, venture capital, zolucatetide

Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson

Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets

1 week ago talkbio0Tagged cancer drug development, Capital, Fibromatosis, Aggressive, fidelity, FOG-001, FogPharma, Helicon peptide platform, Janus Henderson, Malignant neoplasm of prostate, Parabilis Medicines, Rheumatoid Arthritis, Series F financing, targets, venture capital, zolucatetide

Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson

Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets

1 week ago talkbio0Tagged cancer drug development, Capital, Fibromatosis, Aggressive, fidelity, FOG-001, FogPharma, Helicon peptide platform, Janus Henderson, Malignant neoplasm of prostate, Parabilis Medicines, Rheumatoid Arthritis, Series F financing, targets, venture capital, zolucatetide

Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson

Parabilis raises $305M to advance Helicon peptide cancer drugs against ‘undruggable’ targets

1 week ago talkbio0Tagged cancer drug development, Capital, Fibromatosis, Aggressive, fidelity, FOG-001, FogPharma, Helicon peptide platform, Janus Henderson, Malignant neoplasm of prostate, Parabilis Medicines, Rheumatoid Arthritis, Series F financing, targets, venture capital, zolucatetide

Parabilis Medicines; FogPharma; $305 million; Series F financing; undruggable targets; Helicon peptide platform; zolucatetide; FOG-001; desmoid tumors; prostate cancer; cancer drug development; venture capital; RA Capital; Fidelity; Janus Henderson

Alumis’ TYK2 Inhibitor Envudeucitinib Succeeds in Phase 3 Psoriasis Trials, Plans FDA Filing

1 week ago talkbio0Tagged Alumis, Approved, envudeucitinib, Phase 3 trials, Psoriasis, Psoriasis Area and Severity Index Clinical Classification, TYK2 Inhibitor, United States Food and Drug Administration

Alumis; envudeucitinib; TYK2 inhibitor; psoriasis; Phase 3 trials; FDA approval; PASI 75

RTW-backed startup Yarrow Bioscience signs autoimmune antibody deal with China’s GenSci

4 weeks ago talkbio0Tagged anti-TSHR antibody, Antibodies, Autoimmune, Changchun GeneScience Pharmaceutical, China, GenSci, GS-098, Investments, RTW, strategic partnership, Thyroid associated opthalmopathies, Yarrow Bioscience, YB-101

RTW Investments; Yarrow Bioscience; GenSci; Changchun GeneScience Pharmaceutical; autoimmune; antibody; GS-098; YB-101; anti-TSHR antibody; thyroid eye disease; China; ex-China rights; strategic partnership; licensing deal

Insilico Medicine and TaiGen sign exclusive licensing deal for AI-designed PHD inhibitor ISM4808 to treat anemia in chronic kidney disease

1 month ago talkbio0Tagged AI-driven, Anemia, CDE, China, Chronic Kidney Diseases, Clearance, clinical-stage biotech, Drug Discovery, Generative AI, Indonesian language, Insilico Medicine, ISM4808, License Agreement, Oral cavity, Ph.D., Pharma, PHD inhibitor, TaiGen Biotechnology

Insilico Medicine; TaiGen Biotechnology; license agreement; ISM4808; PHD inhibitor; anemia of Chronic Kidney Disease; CKD anemia; AI-driven drug discovery; Pharma.AI; Greater China rights; oral PHD inhibitor; IND clearance; China CDE; generative AI; clinical-stage biotech

NiKang Therapeutics Presents NKT5097: First-in-Class CDK2/4 Dual Degrader at SABCS 2025

1 month ago talkbio0Tagged Cancer Therapeutic Procedure, CDK2/4 degrader, Malignant neoplasm of breast, NiKang Therapeutics, SABCS

NiKang Therapeutics; NKT5097; CDK2/4 degrader; SABCS 2025; cancer therapy; breast cancer